Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 million - GLUE News | RalliesMonte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 million
G
GLUE• Quarterly results and pipeline updates
- Monte Rosa Therapeutics posted a net loss of $43.4 million in Q2 2026, widening from a $12.3 million loss a year earlier.
- Revenue fell 61% to $9 million, while R&D expenses climbed 56% to $48 million on higher MRT-8102 and other program spending.
- Cash, cash equivalents, restricted cash, and marketable securities totaled $626 million as of June 30, down from $671.2 million as of March 31.
- Completed enrollment and dosing in the MRT-8102 GFORCE-1 Phase 1 study in elevated CVD-risk subjects; readout is expected in H2 2026.
- Activated the MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide in mCRPC; Novartis activated a Phase 2a/b study of MRT-6160 in Sjögren's disease.
